Breadcrumb

What's New at the RI-MUHC ?

15,000 COVID-19 tests produced by McGill University and the RI-MUHC: a step toward Canadian self-sufficiency

In July 2020, the McGill University Health Centre’s (MUHC's) Department of Clinical...

Protecting lung cancer patients from COVID-19 – and learning from the experience

A study led by Dr. Nathaniel Bourganim tracked changes in treatment plans

New study of therapy options in metastatic melanoma

RI-MUHC researchers lead “real-world” analysis of treatment patterns with checkpoint inhibitors

Nip it in the bud: New study will attack SARS-Cov2 where it multiplies

RI-MUHC researchers initiate a clinical trial of ciclesonide to possibly prevent mild cases of COVID-19 from worsening

Serious Flaws in Studies Linking COVID-19 and Air Pollution

Studies have yet to prove this link, say Carleton and McGill University epidemiologists

Systematic testing of groups at increased risk of SARS-CoV-2: an affordable and reasonable approach

In a new cost-analysis study, researchers recommend widespread testing of...

Old drug, new therapy: RI-MUHC-sponsored phase III clinical trial ready to test repurposed dapsone to tone down lung inflammation caused by COVID-19

Reformulated and patented version of well-known generic drug could prove to be a quick, safe and cost-effective way to accelerate recovery and prevent hospitalizations

COVID-19 Q&A on dealing with pandemic fatigue

“We need to strike a balance and take our anxiety down from an unhealthy to a manageable level,” says researcher Jason Harley

New study shows that persistence of ADHD into adulthood is an important predictor of car crash risk

RI-MUHC researcher Dr. Lily Hechtman is senior author of a 20-year study

Research suggests greater access to specific HIV and tuberculosis medications is needed worldwide

Postdoctoral fellows at the RI-MUHC carried out primary statistical analyses for study published in The Lancet

Learn more about the RI-MUHC